What is Hexarelin 2MG & 5MG

Hexarelin 2MG & 5MG is a synthetic hexapeptide of the growth hormone secretagogue (GHS) class studied in research for its exceptionally potent ability to stimulate growth hormone release and support cardiovascular health. It is intended exclusively for research use.

Regarding its chemical identity, Hexarelin has a molecular formula of C47H58N12O6 and a molecular weight of 887.0 g/mol. Its reported canonical sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Hexarelin.

Product for research use.

Mechanism of action of Hexarelin

Hexarelin acts as an agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). It triggers a massive, dose-dependent release of Growth Hormone (GH) from the pituitary. Unlike ghrelin, it does not significantly stimulate appetite. It also binds to cardiac receptors (CD36), offering direct cardioprotective effects.

Pharmacokinetics and pharmacodynamics of Hexarelin

Hexarelin exhibits a short plasma half-life of approximately 50 to 70 minutes. Its rapid action causes a sharp spike in GH levels, followed by a rapid decline, mimicking physiological pulsatility but with much greater intensity.

Scientific evidence on Hexarelin

The available evidence on Hexarelin is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in models of severe growth hormone deficiency, ischemic heart disease, and age-related frailty. Evidence indicates it is one of the strongest GH releasers available, and its unique affinity for CD36 receptors has driven significant research into myocardial preservation after ischemia.

Hexarelin applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Hexarelin protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Hexarelin, so no trial schemes or quantities are specified.

The presentations of this product (2MG & 5MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Hexarelin

As a general guideline for laboratory handling, lyophilized peptides such as Hexarelin are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 2MG & 5MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Hexarelin Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Hexarelin security profile

The documented safety information in open sources for Hexarelin is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

The intense spike in GH can lead to rapid desensitization of the pituitary receptors if administered continuously. It has also been shown to significantly elevate prolactin and cortisol levels in a dose-dependent manner.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Hexarelin in a comparative context

Compared to GHRP-6 or Ipamorelin, Hexarelin does not stimulate appetite. However, it causes the largest release of GH and the most significant elevations in cortisol and prolactin, making it the most potent but least selective of the GHRPs.

History and development of Hexarelin

Developed in the early 1990s as a highly stable, potent synthetic analogue of GHRP-6. It was extensively studied in clinical trials for growth hormone deficiency but was largely abandoned for commercial pharmaceutical development in favor of longer-acting therapies.